Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given a consensus rating of “Moderate Buy” by the five research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $5.83.

A number of equities research analysts have issued reports on SRTS shares. Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Lake Street Capital lowered their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th.

Insider Buying and Selling at Sensus Healthcare

In other news, Director Eric Sachetta acquired 37,537 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was bought at an average price of $3.44 per share, with a total value of $129,127.28. Following the acquisition, the director owned 267,480 shares in the company, valued at $920,131.20. The trade was a 16.32% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders acquired 120,171 shares of company stock worth $405,230. 10.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. EP Wealth Advisors LLC purchased a new stake in Sensus Healthcare during the 2nd quarter worth about $49,000. BlackRock Inc. bought a new stake in shares of Sensus Healthcare during the 2nd quarter valued at about $252,000. Finally, Bank of New York Mellon Corp purchased a new stake in Sensus Healthcare in the second quarter valued at approximately $303,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $3.41 on Friday. The firm has a 50-day moving average of $3.00 and a 200-day moving average of $3.47. Sensus Healthcare has a one year low of $2.66 and a one year high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $4.60 million.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc. is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin. Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.